Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drainage technique works best when cancer blocks the bile duct?

NCT ID NCT07817602

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Pancreatic and other biliopancreatic cancers often block the bile duct, causing jaundice and serious infections. Doctors use endoscopic procedures to place stents that restore bile flow, but several techniques exist and it is unclear which works best. This study follows 300 patients to compare how often stents fail and how well each technique performs. The goal is to help doctors choose the most effective drainage method for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic biliary drainage procedures, including ERCP and EUS-guided techniques
What this could lead to
If one technique proves better, doctors could choose the safest, most effective drainage method for patients with malignant bile duct blockage.
What could go wrong
This is an observational comparison, not a randomized trial, so differences between techniques may reflect patient selection rather than the procedures themselves. Results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with distal biliary obstruction of malignant etiology (pancreas, ampulloma, compressive metastatic lymphadenopathy, other distal tumors, with planned biliary drainage.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Distal biliary obstruction of malignant etiology (pancreas, ampulloma, compressive metastatic lymphadenopathy, other distal tumors). * Decision made to proceed with biliary drainage. * Patient informed and no objection raised, in accordance with the MR-004 framework and COPPINE procedure Exclusion Criteria: * The subject is participating in another study * The subject unable to expression on-objection * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Proximal/hilar or benign obstruction (non-tumoral lesions). * Contraindication to endoscopy/anesthesia (uncorrectable hemodynamic instability, uncontrolled coagulation disorders, etc.). * History of prior biliary drainage. * Pregnant or breastfeeding patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary drainage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary drainage Endoscopic ultrasound-guided drainage Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Nancy

    Vandœuvre-lès-Nancy, France

  • CHU Dupuytren

    Limoges, France

  • Chu Nimes

    Nîmes, 30900, France

  • Hôpital Edouard Herriot

    Lyon, France

  • Hôpital Saint-Antoine

    Paris, France

  • Hôpital Saint-Eloi

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.